SCHEDULE 13G: Ikarian Capital and Neil Shahrestani Disclose 8.7% Stake in Aethlon Medical, Inc.

Investment firm Ikarian Capital, LLC and its controller Neil Shahrestani have disclosed a passive 8.7% beneficial ownership stake in Aethlon Medical, Inc., totaling 1,229,285 shares.

Summary

• Ikarian Capital, LLC and Neil Shahrestani (collectively, the "Reporting Persons") have filed a Schedule 13G indicating beneficial ownership of Aethlon Medical, Inc. common stock.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 1,229,285 shares of Aethlon Medical, Inc. Common Stock.
• This ownership represents 8.7% of the Issuer's outstanding Common Stock.
• The percentage is calculated based on 14,114,096 shares of Common Stock outstanding as of January 30, 2025, as disclosed in Aethlon Medical's Regulation A Offering Statement.
• Ikarian Capital, LLC, a Delaware limited liability company, serves as an investment adviser to Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts, which are the record owners of the securities.
• Neil Shahrestani indirectly controls Ikarian Capital, LLC and is therefore deemed to indirectly beneficially own the securities.
• The Reporting Persons certify that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Aethlon Medical, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory filing.

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by an institutional investor in Aethlon Medical, Inc., a company likely operating in the healthcare or biotechnology sector given its name. Such disclosures are common for investment firms taking substantial, non-controlling stakes in public companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant 8.7% stake by an institutional investor like Ikarian Capital, LLC may be viewed positively by other shareholders as a vote of confidence, potentially increasing investor interest and liquidity. However, as it's a passive stake, it does not imply active engagement or influence on company strategy.

Key Dates

Keywords

Aethlon Medical, Ikarian Capital, Neil Shahrestani, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Healthcare, Biotechnology